Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Metrics to compare | TKNO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTKNOPeersSector | |
---|---|---|---|---|
P/E Ratio | −14.2x | −4.0x | −0.6x | |
PEG Ratio | −0.30 | −0.90 | 0.00 | |
Price/Book | 5.2x | 2.4x | 2.6x | |
Price / LTM Sales | 12.4x | 2.7x | 3.2x | |
Upside (Analyst Target) | −5.2% | 48.5% | 46.2% | |
Fair Value Upside | Unlock | 7.2% | 7.0% | Unlock |